Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

Immunoglobulin Light-chain Amyloidosis Clinical Trial

Official title:
Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis: A Randomized Controlled Trial

Status Not yet recruiting

Clinical Trial Summary

The purpose of this clinical trial is to evaluate whether specific probiotic can reduce gastrointestinal symptoms and improves therapeutic response, on a background of Bortezomib+dexamethasone or Bortezomib+dexamethasone combined with daratumumab therapy, for naive AL amyloidosis patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amyloidosis
Immunoglobulin Light-chain Amyloidosis

Clinical Trial Details

NCT number	NCT05776940
Study type	Interventional
Source	Air Force Military Medical University, China
Contact	Shiren Sun, Doctor
Phone	18520955728
Email	1019282726@qq.com
Status	Not yet recruiting
Phase	Phase 3
Start date	March 31, 2023
Completion date	March 31, 2026

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04659798` - A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
	Recruiting	`NCT04612582` - Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis	Phase 4